| Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) KT Flaherty, RJ Gray, AP Chen, S Li, LM McShane, D Patton, SR Hamilton, ... Journal of Clinical Oncology 38 (33), 3883-3894, 2020 | 204 | 2020 |
| The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design KT Flaherty, R Gray, A Chen, S Li, D Patton, SR Hamilton, PM Williams, ... JNCI: Journal of the National Cancer Institute 112 (10), 1021-1029, 2020 | 166 | 2020 |
| Nivolumab is effective in mismatch repair–deficient noncolorectal cancers: Results from arm Z1D—A subprotocol of the NCI-MATCH (EAY131) study NS Azad, RJ Gray, MJ Overman, JD Schoenfeld, EP Mitchell, JA Zwiebel, ... Journal of Clinical Oncology 38 (3), 214, 2020 | 135 | 2020 |
| Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the National Cancer Institute–Children's … DW Parsons, KA Janeway, DR Patton, CL Winter, B Coffey, PM Williams, ... Journal of Clinical Oncology 40 (20), 2224-2234, 2022 | 61 | 2022 |
| Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial. DW Parsons, KA Janeway, D Patton, B Coffey, PM Williams, SR Hamilton, ... Journal of Clinical Oncology 37 (15_suppl), 10011-10011, 2019 | 33 | 2019 |
| The NCI-MATCH trial: lessons for precision oncology PJ O’Dwyer, RJ Gray, KT Flaherty, AP Chen, S Li, V Wang, LM McShane, ... Nature medicine 29 (6), 1349-1357, 2023 | 32 | 2023 |
| Phase II study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: arm E of the NCI-COG … OS Eckstein, CE Allen, PM Williams, S Roy-Chowdhuri, DR Patton, ... Journal of Clinical Oncology 40 (20), 2235, 2022 | 27 | 2022 |
| Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis BA Conley, R Gray, A Chen, P O’Dwyer, C Arteaga, B Coffey, D Patton, ... Cancer research 76 (14_Supplement), CT101-CT101, 2016 | 20 | 2016 |
| O37: Nivolumab in mismatch-repair deficient (MMR-d) cancers: NCI-MATCH Trial (Molecular Analysis for Therapy Choice) arm Z1D preliminary results N Azad, M Overman, R Gray, J Schoenfeld, C Arteaga, B Coffey, D Patton, ... 32nd Annual Meeting and Pre-Conference Programs of the Society for …, 2017 | 12 | 2017 |
| Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C SN Chi, JS Yi, PM Williams, S Roy-Chowdhuri, DR Patton, BD Coffey, ... JNCI: Journal of the National Cancer Institute 115 (11), 1355-1363, 2023 | 11 | 2023 |
| Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B). A Lee, AJ Chou, PM Williams, S Roy-Chowdhuri, DR Patton, BD Coffey, ... Journal of Clinical Oncology 41 (16_suppl), 10007-10007, 2023 | 5 | 2023 |
| COVID-19 SeroHub, an online repository of SARS-CoV-2 seroprevalence studies in the United States ND Freedman, L Brown, LM Newman, JM Jones, TJ Benoit, F Averhoff, ... Scientific Data 9 (1), 727, 2022 | 5 | 2022 |
| Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C). SN Chi, JS Yi, PM Williams, S Roy-Chowdhuri, DR Patton, B Coffey, ... Journal of Clinical Oncology 40 (16_suppl), 10009-10009, 2022 | 5 | 2022 |
| Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J). KT Vo, AJ Sabnis, PM Williams, S Roy-Chowdhuri, DR Patton, B Coffey, ... Journal of Clinical Oncology 40 (16_suppl), 3009-3009, 2022 | 5 | 2022 |
| Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial. CE Allen, O Eckstein, PM Williams, S Roy-Chowdhuri, DR Patton, ... Journal of Clinical Oncology 39 (15_suppl), 10008-10008, 2021 | 3 | 2021 |
| Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I). ME Macy, R Mody, JM Reid, J Piao, L Saguilig, TA Alonzo, SL Berg, E Fox, ... Journal of Clinical Oncology 41 (16_suppl), 10006-10006, 2023 | 2 | 2023 |
| Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols. DW Parsons, KA Janeway, DR Patton, J Lee, B Coffey, PM Williams, ... Journal of Clinical Oncology 39 (15_suppl), 10007-10007, 2021 | 2 | 2021 |
| Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131) MA Gouda, F Janku, Y Yuan, L Drusbosky, AP Chen, K Patel, ... Molecular Cancer Therapeutics 22 (12_Supplement), B007-B007, 2023 | | 2023 |
| Comparison of AYA versus non-AYA ovarian cancer genomic landscape in NCI-MATCH trial. H Sankaran, Y Kotliarov, Y Zhao, SM Temkin, PM Williams, CA Karlovich, ... Journal of Clinical Oncology 40 (16_suppl), e17617-e17617, 2022 | | 2022 |
| The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design (vol 112, djz245, 2020) KT Flaherty, R Gray, A Chen, S Li, D Patton, SR Hamilton, PM Williams, ... JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 114 (2), 325-325, 2022 | | 2022 |
D.Williams ParsonsBaylor College of MedicineVerified email at bcm.edu
